Zachary A Marcum1, Rod Walker2, Jennifer F Bobb2, Mo-Kyung Sin3, Shelly L Gray1, James D Bowen4, Wayne McCormick5, Susan M McCurry6, Paul K Crane7, Eric B Larson2. 1. Department of Pharmacy, School of Pharmacy, University of Washington, Seattle, Washington. 2. Kaiser Permanente Washington Health Research Institute, Kaiser Permanente Washington, Seattle, Washington. 3. Seattle University, College of Nursing, Seattle, Washington. 4. Swedish Medical Center, Seattle, Washington. 5. Department of Medicine, Division of Gerontology and Geriatric Medicine, University of Washington, Seattle, Washington. 6. School of Nursing, University of Washington, Seattle, Washington. 7. Department of Medicine, Division of General Internal Medicine, University of Washington, Seattle, Washington.
Abstract
OBJECTIVES: To evaluate associations between high-density lipoprotein cholesterol (HDL) and non-HDL-C levels at specific ages and subsequent Alzheimer's disease (AD) risk. DESIGN: Prospective population-based cohort study. SETTING: Adult Changes in Thought (ACT) Study. PARTICIPANTS: Individuals aged 65 and older with no dementia at ACT Study entry. We identified separate, partially overlapping subcohorts of ACT participants who were eligible for each age band-specific analysis (50-59, n = 1,088; 60-69, n = 2,852; 70-79, n = 2,344; 80-89, n = 537). MEASUREMENTS: Exposure consisted of clinical measures of total cholesterol (TC) and HDL-C from laboratory data during a given age band. Outcomes of incident AD were assessed post-age band using standard research diagnostic criteria. Statistical analyses used adjusted Cox proportional hazards regression models for each exposure and outcome pair within an age band. Cholesterol exposures were modeled using cubic splines. RESULTS: For non-HDL-C, we found a statistically significant association with AD risk in the 60 to 69 (omnibus p = .005) and 70 to 79 (omnibus p = .04) age bands, suggesting a potential U-shaped relationship (greater risk at low and high levels). For example, in people aged 60 to 69, those with an average non-HDL-C level of 120 mg/DL had a 29% greater AD hazard (hazard ratio (HR)=1.29, 95% confidence interval (CI)=1.04-1.61) than those with an average non-HDL-C level of 160 mg/dL, whereas those with an average non-HDL-C level of 210 mg/dL had a 16% greater hazard (HR=1.16, 95% CI=1.01-1.33). We did not find a statistically significant association between HDL-C and AD risk. CONCLUSION: People with low (120 mg/dL) and high (210 mg/dL) non-HDL-C levels during their 60s and 70s had modestly higher risk of AD than those with intermediate (160 mg/dL) levels. The extreme age bands (50s and 80s) had small sample sizes. J Am Geriatr Soc 66:2344-2352, 2018.
OBJECTIVES: To evaluate associations between high-density lipoprotein cholesterol (HDL) and non-HDL-C levels at specific ages and subsequent Alzheimer's disease (AD) risk. DESIGN: Prospective population-based cohort study. SETTING: Adult Changes in Thought (ACT) Study. PARTICIPANTS: Individuals aged 65 and older with no dementia at ACT Study entry. We identified separate, partially overlapping subcohorts of ACT participants who were eligible for each age band-specific analysis (50-59, n = 1,088; 60-69, n = 2,852; 70-79, n = 2,344; 80-89, n = 537). MEASUREMENTS: Exposure consisted of clinical measures of total cholesterol (TC) and HDL-C from laboratory data during a given age band. Outcomes of incident AD were assessed post-age band using standard research diagnostic criteria. Statistical analyses used adjusted Cox proportional hazards regression models for each exposure and outcome pair within an age band. Cholesterol exposures were modeled using cubic splines. RESULTS: For non-HDL-C, we found a statistically significant association with AD risk in the 60 to 69 (omnibus p = .005) and 70 to 79 (omnibus p = .04) age bands, suggesting a potential U-shaped relationship (greater risk at low and high levels). For example, in people aged 60 to 69, those with an average non-HDL-C level of 120 mg/DL had a 29% greater AD hazard (hazard ratio (HR)=1.29, 95% confidence interval (CI)=1.04-1.61) than those with an average non-HDL-C level of 160 mg/dL, whereas those with an average non-HDL-C level of 210 mg/dL had a 16% greater hazard (HR=1.16, 95% CI=1.01-1.33). We did not find a statistically significant association between HDL-C and AD risk. CONCLUSION:People with low (120 mg/dL) and high (210 mg/dL) non-HDL-C levels during their 60s and 70s had modestly higher risk of AD than those with intermediate (160 mg/dL) levels. The extreme age bands (50s and 80s) had small sample sizes. J Am Geriatr Soc 66:2344-2352, 2018.
Authors: G Li; J B Shofer; W A Kukull; E R Peskind; D W Tsuang; J C S Breitner; W McCormick; J D Bowen; L Teri; G D Schellenberg; E B Larson Journal: Neurology Date: 2005-10-11 Impact factor: 9.910
Authors: I L Notkola; R Sulkava; J Pekkanen; T Erkinjuntti; C Ehnholm; P Kivinen; J Tuomilehto; A Nissinen Journal: Neuroepidemiology Date: 1998 Impact factor: 3.282
Authors: L M Refolo; B Malester; J LaFrancois; T Bryant-Thomas; R Wang; G S Tint; K Sambamurti; K Duff; M A Pappolla Journal: Neurobiol Dis Date: 2000-08 Impact factor: 5.996
Authors: M M Mielke; P P Zandi; H Shao; M Waern; S Östling; X Guo; C Björkelund; L Lissner; I Skoog; D R Gustafson Journal: Neurology Date: 2010-11-10 Impact factor: 9.910
Authors: D Tsuang; W Kukull; L Sheppard; R L Barnhart; E Peskind; S D Edland; G Schellenberg; M Raskind; E B Larson Journal: J Am Geriatr Soc Date: 1996-06 Impact factor: 5.562
Authors: Gill Livingston; Andrew Sommerlad; Vasiliki Orgeta; Sergi G Costafreda; Jonathan Huntley; David Ames; Clive Ballard; Sube Banerjee; Alistair Burns; Jiska Cohen-Mansfield; Claudia Cooper; Nick Fox; Laura N Gitlin; Robert Howard; Helen C Kales; Eric B Larson; Karen Ritchie; Kenneth Rockwood; Elizabeth L Sampson; Quincy Samus; Lon S Schneider; Geir Selbæk; Linda Teri; Naaheed Mukadam Journal: Lancet Date: 2017-07-20 Impact factor: 202.731
Authors: Shelly L Gray; Sascha Dublin; Onchee Yu; Rod Walker; Melissa Anderson; Rebecca A Hubbard; Paul K Crane; Eric B Larson Journal: BMJ Date: 2016-02-02
Authors: Zachary A Marcum; Rod Walker; Jennifer F Bobb; Mo-Kyung Sin; Shelly L Gray; James D Bowen; Wayne McCormick; Susan M McCurry; Paul K Crane; Eric B Larson Journal: J Am Geriatr Soc Date: 2019-03-20 Impact factor: 5.562
Authors: Melina G H E den Brok; Esmé Eggink; Marieke P Hoevenaar-Blom; Willem A van Gool; Eric P Moll van Charante; Edo Richard; Jan Willem van Dalen Journal: Neurology Date: 2022-08-02 Impact factor: 11.800
Authors: Supraja N Avula; Ke-Li-Ta N Joseph; Chibuzor V Onuchukwu; Vishwanath Thondamala; Shashwat Shrivastava; Anusha R Namburi; Lubna Mohammed Journal: Cureus Date: 2022-04-22
Authors: Emily B Button; Guilaine K Boyce; Anna Wilkinson; Sophie Stukas; Arooj Hayat; Jianjia Fan; Brennan J Wadsworth; Jerome Robert; Kris M Martens; Cheryl L Wellington Journal: Alzheimers Res Ther Date: 2019-05-13 Impact factor: 6.982